Vera Therapeutics (NASDAQ:VERA) Shares Up 3.6%

Vera Therapeutics, Inc. (NASDAQ:VERA) was up 3.6% on Friday . The company traded as high as $35.94 and last traded at $35.90. Approximately 13,510 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 1,098,632 shares. The stock had previously closed at $34.66.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Raymond James increased their price target on Vera Therapeutics from $57.00 to $68.00 and gave the stock a “strong-buy” rating in a research report on Friday, May 10th. JPMorgan Chase & Co. increased their target price on Vera Therapeutics from $60.00 to $65.00 and gave the company an “overweight” rating in a research report on Friday, May 31st. Wedbush boosted their price target on shares of Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a report on Thursday, March 21st. Finally, Guggenheim reaffirmed a “buy” rating and set a $56.00 price objective on shares of Vera Therapeutics in a report on Friday, April 5th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $42.86.

Vera Therapeutics Trading Up 4.4 %

The company has a debt-to-equity ratio of 0.14, a quick ratio of 28.63 and a current ratio of 28.63. The company has a 50 day moving average of $39.05 and a 200 day moving average of $35.46. The stock has a market capitalization of $1.98 billion, a price-to-earnings ratio of -17.65 and a beta of 1.04.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). On average, research analysts predict that Vera Therapeutics, Inc. will post -2.34 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In related news, CFO Sean Grant sold 99,828 shares of the stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $39.61, for a total value of $3,954,187.08. Following the completion of the sale, the chief financial officer now owns 66,337 shares of the company’s stock, valued at $2,627,608.57. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, CFO Sean Grant sold 99,828 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total transaction of $3,954,187.08. Following the completion of the sale, the chief financial officer now directly owns 66,337 shares in the company, valued at $2,627,608.57. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Joseph R. Young sold 5,714 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $40.00, for a total transaction of $228,560.00. Following the completion of the transaction, the senior vice president now owns 53,171 shares in the company, valued at $2,126,840. The disclosure for this sale can be found here. Insiders own 21.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. increased its holdings in Vera Therapeutics by 20.8% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,000 shares of the company’s stock valued at $172,000 after purchasing an additional 688 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Vera Therapeutics by 12.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,116 shares of the company’s stock valued at $356,000 after buying an additional 2,537 shares during the last quarter. American International Group Inc. lifted its holdings in Vera Therapeutics by 17.6% during the 1st quarter. American International Group Inc. now owns 19,764 shares of the company’s stock worth $852,000 after buying an additional 2,957 shares during the last quarter. SG Americas Securities LLC raised its position in shares of Vera Therapeutics by 54.9% during the 1st quarter. SG Americas Securities LLC now owns 11,941 shares of the company’s stock worth $515,000 after acquiring an additional 4,232 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Vera Therapeutics by 96.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,117 shares of the company’s stock worth $436,000 after purchasing an additional 4,974 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.